OncoMatch/Clinical Trials/NCT06568094
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
Is NCT06568094 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for prostate cancer.
Treatment: HRS-5041 tablets · Abiraterone Acetate tablets（II） · Prednisone Acetate tablets · Docetaxel · HRS-1167 tablets · SHR2554 tablets — The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in subjects with advanced prostate cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Prostate Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06568094 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages